Sanofi (NASDAQ:SNY) Shares Purchased by Farther Finance Advisors LLC

Farther Finance Advisors LLC raised its stake in shares of Sanofi (NASDAQ:SNY) by 30.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,739 shares of the company’s stock after buying an additional 878 shares during the period. Farther Finance Advisors LLC’s holdings in Sanofi were worth $180,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Sequoia Financial Advisors LLC increased its stake in Sanofi by 2.1% during the 4th quarter. Sequoia Financial Advisors LLC now owns 21,003 shares of the company’s stock valued at $1,013,000 after buying an additional 425 shares during the period. HighTower Advisors LLC boosted its position in shares of Sanofi by 3.4% during the 4th quarter. HighTower Advisors LLC now owns 91,071 shares of the company’s stock valued at $4,392,000 after purchasing an additional 2,971 shares in the last quarter. Wealthfront Advisers LLC bought a new position in shares of Sanofi during the 4th quarter valued at about $1,908,000. Meriwether Wealth & Planning LLC bought a new position in shares of Sanofi during the 4th quarter valued at about $587,000. Finally, Amundi boosted its position in shares of Sanofi by 11.1% during the 4th quarter. Amundi now owns 630,063 shares of the company’s stock valued at $31,017,000 after purchasing an additional 63,195 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of SNY opened at $58.60 on Thursday. Sanofi has a one year low of $45.22 and a one year high of $60.12. The company has a 50-day moving average of $54.22 and a two-hundred day moving average of $52.89. The stock has a market cap of $148.72 billion, a price-to-earnings ratio of 23.53, a PEG ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on SNY shares. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.